• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current therapeutic research, clinical and experimental. >Cross-Sectional Survey to Assess the Status of Lipid Management in High-Risk Patients With Dyslipidemia: Clinical Impact of Combination Therapy With Ezetimibe
【24h】

Cross-Sectional Survey to Assess the Status of Lipid Management in High-Risk Patients With Dyslipidemia: Clinical Impact of Combination Therapy With Ezetimibe

机译：横断面调查评估高危血脂异常患者血脂管理状况：联合治疗与依泽替米贝的临床影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Previous retrospective surveys have shown that lipid management goals are well achieved in patients with dyslipidemia at relatively low risk for atherosclerotic diseases. However, more than half of patients in high-risk groups have not achieved the management goals. Since these surveys, newer medications, including rosuvastatin and ezetimibe, have emerged in clinical practice that may influence lipid management.OBJECTIVE: To assess the current status of lipid management in high-risk patients, we conducted a cross-sectional study between January and March 2010.METHODS: Eligible patients were those with dyslipidemia who were classified into the primary prevention high-risk or secondary prevention groups according to the Japan Atherosclerosis Society guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases. Patient data were collected from 300 randomly selected physicians at hospitals and clinics across Japan if patients had been receiving the same statin with or without other lipid-lowering agents for >=3 months. The main outcome was the percentage of patients who achieved the serum LDL-C goal according to the guideline.RESULTS: Data were collected from 1720 patients. The LDL-C goal was achieved in 56.5% of patients (447 of 791) in the primary prevention high-risk group and in 24.5% (103 of 420) in the secondary prevention group by statin monotherapy. For patients who had not reached the LDL-C goal with statin therapy alone, 53.8% (113 of 210) in the primary prevention high-risk group and 63.8% (111 of 174) in the secondary prevention group achieved their lipid management goal with the addition of ezetimibe. Ezetimibe significantly lowered mean serum LDL-C levels by 17.9% to 34.6% when added to various statins (P < 0.001). CONCLUSIONS: Although strong statins are available, lipid management in high-risk patients remains unsatisfactory. More aggressive treatment is needed for these patients.
机译：背景：以前的回顾性调查显示，血脂异常患者的动脉粥样硬化疾病风险相对较低，脂质管理目标已实现。但是，高风险组中超过一半的患者尚未达到管理目标。自这些调查以来，临床实践中出现了可能会影响脂质管理的新型药物，包括瑞舒伐他汀和依泽替米贝。目的：为评估高危患者脂质管理的现状，我们在1月至3月进行了一项横断面研究2010年方法：符合条件的患者是血脂异常的患者，根据日本动脉粥样硬化学会诊断和预防动脉粥样硬化性心血管疾病的指南，血脂异常患者被分为一级预防高危或二级预防组。如果患者在≥3个月内接受或不接受其他降脂药的相同他汀类药物，则从日本各地医院和诊所的300位随机选择的医生中收集患者数据。主要结果是根据指南达到血清LDL-C目标的患者百分比。结果：数据来自1720例患者。通过他汀类药物单药治疗，一级预防高危组中56.5％的患者（791名中的447名）和二级预防组中24.5％（420名中的103名）的患者达到了LDL-C目标。对于仅通过他汀类药物治疗仍未达到LDL-C目标的患者，一级预防高危组中53.8％（210的113）和二级预防组中63.8％（174的111）达到了他们的血脂管理目标依泽替米贝的添加。当加入各种他汀类药物时，依泽替米贝显着降低平均血清LDL-C水平17.9％至34.6％（P <0.001）。结论：尽管可获得强大的他汀类药物，但高危患者的血脂管理仍不能令人满意。这些患者需要更积极的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号